Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ABL-103 by Aurum Biosciences for Inflammation: Likelihood of Approval
ABL-103 is under clinical development by Aurum Biosciences and currently in Phase II for Inflammation. According to GlobalData, Phase II...
Data Insights
ABL-103 by ABL Bio for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
ABL-103 is under clinical development by ABL Bio and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...